click enter text
visibl valuabl recent host investor meet
manag headquart washington dc includ cfo matt
mcgrew vice-president ir matt gugino director ir brian pfeifer key messag
growth/r d/commerci flywheel across dhr busi run
well seri signific transact last five year
elev invest d/commerci perform
evid model work manag see caus expect
meaning chang growth/margin trend outsid major advers macro
event remain outperform rate top line acceler visibl
bridg achiev steadi state growth organ
ex-g ls notabl risk around growth rate larg macro
environ includ china trade sign
concern regard broad trend ge add organ growth
gm net increas core annual oper margin
expans target expect remain year spend
drive sale new product innov expect off-set gross
margin cost save benefit
ge detail ge biopharma acquisit expect close
approv multipl jurisdict remain outstand manag
feel make progress evidenc agreement sell certain
busi life scienc sartoriu revenu total
impact growth rate portfolio move exclud dental
includ ge busi overal growth rate ge
busi renam cytiva mid ebita margin similar ebitda
margin omx expect limit given rel strong margin
focu deliv oper profit dollar growth
expect cost synergi phase approxim evenli
year larg cog suppli chain save believ
upsid guidanc ge busi accret like higher
strong revenu perform continu financ less
expens origin forecast
addit takeaway meet page
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
consensu somewhat opaqu consensu estim move direct incorpor
portfolio move ep broker look made chang
detail estim move piec note ep estim
high end street rang
pharma strength biopharma overal run trend last coupl year cell gene
therapi come strong small base earli market cell gene therapi growth
expect continu year long-term could benefit combin pall cytiva
effort bioproduct grow dd core pharma grow hsd larg
focus volum growth bioprocess industri manag said interest get
player continu serv filtrat chromatographi tool slower growth recent
small molecul larg relat refer lab consolid impact sciex small molecul expect
continu grow continu invest space
commentari limit manag limit comment could make regard
given current exchang offer take-away acceler divestitur remain
interest larg allow compani report manag without complic
ownership overhang also note manag commentari prior exchang offer spin
would allow pursu transact otherwis would materi
greater abil gener sharehold return manag felt over-invest
area dental segment prepar compani success
tidbit touch number topic briefli meet guidanc includ ge
prorat amount includ base expect time deal close provid core growth exclud
impact ge see benefit relat japan vat increas pull forward
larg diagnost ad close ge deal annual
ebitda allow compani delev pursu small medium size deal near-term compani
could issu share larger opportun came manag note great read-
industri market compani less sale associ true industri
busi view cyclic pressur busi
page
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
 sale detail mn adjust sell day revenu wr organ bp bpsm estimate bp bp bp bp bp bp bp bpsother estimate bp bp bp bp bp bp bp bp bp bp pall margin organ wr organ bp bpsm bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bpsm bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp
